Meeting Review | The 4th Annual Conference of Chinese Safety Pharmacology Successfully Concluded in Datong, Shanxi

Recently, The 4th (2023) Annual Conference of Chinese Safety Pharmacology, hosted by the Safety Pharmacology Professional Committee of the Chinese Pharmacological Society, and co-organized by the Drug Safety Evaluation Center of China Institute for Radiation Protection and Guangzhou Bay Biomedical Research Institute, was successfully held in Datong, Shanxi Province. Themed "Capturing Global Development Trends in Safety Pharmacology Research, Comprehensively Elevating China's Safety Pharmacology Research Capabilities", the conference invited Dr. Hu Xiaomin, CTO of Joinn Laboratories, Zhang Sucai, General Manager of Non-clinical Business Division, and Zhang Haifei, Senior Director of Safety Pharmacology Department at Joinn (Suzhou), to attend the event.

Dr. Hu Xiaomin delivered a plenary keynote presentation at the conference, sharing insights on Non-clinical Evaluation of Antibody Therapeutics. Qin Shuqi, Senior Study Director of the Toxicology Department at Joinn (Beijing), also gave a parallel session presentation, focusing on Key Considerations for Blood Pressure Monitoring in Safety Pharmacology Studies.

Note: Terminology aligns with standard GLP/CRO industry conventions, including official translations of Joinn Laboratories organizational roles and biomedical research terms, suitable for official corporate news releases and international industry communications.